Entrepreneurs at heart in Biotechnology and Technology
M Ventures is the strategic, corporate venture capital fund of Merck KGaA, Darmstadt, Germany, investing in Biotechnology and Technology. We cover the areas of Healthcare drug development, Life Science tools, Electronics and Frontier Technology & Sustainability.
We invest - with dual strategic and financial foci - into visionary companies that find new ways to: treat the most challenging diseases, empower scientists with cutting-edge research and development tools, develop new solutions that change the way in which information is accessed, stored, processed, and displayed and address some of the most complex challenges in sustainability and technology convergence.
We take an active role in our portfolio companies and team up with entrepreneurs and co-investors to translate innovation towards commercial success.
Latest News
-
Asceneuron Joins Critical Path for Alzheimer’s Disease Consortium
-
beeOLED welcomes New Advisory Board Member and Chairman Gerd Günther
-
Asceneuron Expands Scientific Advisory Board with World Leading Experts in Neurodegenerative Diseases
-
Plexium Announces Appointment of Michael Martin, Ph.D. as President and CEO
-
DISCO Pharmaceuticals launches as the surfaceome company with EUR 20 Million in Seed Financing
-
M Ventures portfolio company Calypso, a Merck KGaA, Darmstadt, Germany spin-out, enters into agreement to be acquired by Novartis